Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aditum Bio
Biotech
US VC launches another biotech with China-licensed asset
Aditum is offering up to $1 billion biobucks to Mabwell for exclusive global licensing rights to a dual-target siRNA candidate.
Gabrielle Masson
Sep 17, 2025 10:30am
VC firm, Chinese biotech launch autoimmune-focused Oblenio Bio
Nov 7, 2024 11:35am
Aditum finds twist on old idea, paying $10M for BTK inhibitor
Apr 28, 2023 6:11am
Before exiting J&J, Gorsky lands on Apple board—Chutes & Ladders
Nov 12, 2021 9:30am
Joe Jimenez's Ancora Bio poaches Sage CMO to revive Taisho drug
Nov 8, 2021 10:50am
Aditum launches Ancora with rights to Taisho's depression drug
Jul 1, 2021 11:51am
